Supriya Lifescience Intrinsic Value
Supriya Lifescience intrinsic value. Supriya Lifescience (SUPRIYA) median intrinsic value is ₹1105.00 from 10 valuation models (range ₹270–₹1799), vs current price ₹899.55 — +22.8% upside (Trading Below Calculated Value), margin of safety 18.6%. Read SUPRIYA dividend track record for the complete payout history and dividend yield track record.
SUPRIYA Valuation Methods Summary — DCF, Graham Number & P/E
Supriya Lifescience intrinsic value across 10 models vs current price ₹899.55 — upside/downside and value range per method. Compare with SUPRIYA fair value to assess whether the stock is under or overvalued.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹543.40 | ₹434.72 - ₹652.08 | -39.6% | EPS: ₹24.70, Sector P/E: 22x |
| Book Value Method | asset | ₹1497.50 | ₹1347.75 - ₹1647.25 | +66.5% | Book Value/Share: ₹748.75, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹1105.00 | ₹994.50 - ₹1215.50 | +22.8% | Revenue/Share: ₹552.50, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹1799.10 | ₹1619.19 - ₹1979.01 | +100.0% | EBITDA: ₹301.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹1579.06 | ₹1263.25 - ₹1894.87 | +75.5% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹395.20 | ₹355.68 - ₹434.72 | -56.1% | EPS Growth: 20.0%, Fair P/E: 16.0x |
| Growth Adjusted P/E | growth | ₹398.29 | ₹358.46 - ₹438.12 | -55.7% | Revenue Growth: 15.0%, Adj P/E: 16.1x |
| ROE Based Valuation | profitability | ₹1732.50 | ₹1559.25 - ₹1905.75 | +92.6% | ROE: 16.5%, P/E Multiple: 14x |
| Graham Defensive Method | conservative | ₹645.07 | ₹580.56 - ₹709.58 | -28.3% | EPS: ₹24.70, BVPS: ₹748.75 |
| Dividend Yield Method | dividend | ₹269.86 | ₹242.87 - ₹296.85 | -70.0% | DPS: ₹1.00, Target Yield: 2.5% |
SUPRIYA Intrinsic Value vs Market Price — All Valuation Models
Supriya Lifescience fair value range ₹270–₹1799 vs current market price ₹899.55 across 10 valuation models. For current market price and key ratios, visit SUPRIYA share price.
SUPRIYA Intrinsic Value Analysis — Undervalued or Overvalued?
Supriya Lifescience median intrinsic value ₹1105.00, current price ₹899.55 — Trading Below Calculated Value by 22.8%, margin of safety 18.6%.
What is the intrinsic value of SUPRIYA?
Based on our comprehensive analysis using 10 different valuation methods, the estimated intrinsic value of Supriya Lifescience (SUPRIYA) is ₹1105.00 (median value). With the current market price of ₹899.55, this represents a +22.8% variance from our estimated fair value.
The valuation range spans from ₹269.86 to ₹1799.10, indicating ₹269.86 - ₹1799.10.
Is SUPRIYA undervalued or overvalued?
Based on our multi-method analysis, Supriya Lifescience (SUPRIYA) appears to be trading below calculated value by approximately 22.8%.
SUPRIYA Financial Health — Key Ratios vs Industry Benchmarks
Supriya Lifescience financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 14.00 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 16.5% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 33.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.65x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
SUPRIYA Cash Flow Quality — Operating & Free Cash Flow
Supriya Lifescience operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2026 | ₹186 Cr | ₹98 Cr | Positive Free Cash Flow | 8/10 |
| March 2025 | ₹165 Cr | ₹89 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹113 Cr | ₹26 Cr | Positive Free Cash Flow | 7/10 |
| March 2023 | ₹64 Cr | ₹2 Cr | Positive Free Cash Flow | 7/10 |
| March 2022 | ₹49 Cr | ₹19 Cr | Positive Free Cash Flow | 7/10 |